TY - JOUR
T1 - Toremifene and tamoxifen are equally effective for early-stage breast cancer
T2 - First results of International Breast Cancer Study Group trials 12-93 and 14-93
AU - Pagani, O.
AU - Gelber, S.
AU - Simoncini, E.
AU - Castiglione-Gertsch, M.
AU - Price, K.
AU - Zahrieh, D.
AU - Gelber, R.
AU - Coates, A.
AU - Goldhirsch, A.
PY - 2004/12
Y1 - 2004/12
N2 - Background: Toremifene is a chlorinated derivative of tamoxifen, developed to improve its risk-benefit profile. The International Breast Cancer Study Group (IBCSG) conducted two complementary randomized trials for peri- and postmenopausal patients with node-positive breast cancer to compare toremifene versus tamoxifen as the endocrine agent and simultaneously investigate a chemotherapy-oriented question. This is the first report of the endocrine comparison after a median follow-up of 5.5 years. Patients and methods: 1035 patients were available for analysis: 75% had estrogen receptor (ER)-positive primary tumors, the median number of involved axillary lymph nodes was three and 81% received prior adjuvant chemotherapy. Results: Toremifene and tamoxifen yielded similar disease-free (DFS) and overall survival (OS): 5-year DFS rates of 72% and 69%, respectively [risk ratio (RR)=0.95; 95% confidence interval (CI)=0.76-1.18]; 5-year OS rates of 85% and 81%, respectively (RR = 1.03; 95% CI = 0.78-1.36). Similar outcomes were observed in the ER-positive cohort. Toxicities were similar in the two treatment groups with very few women (
AB - Background: Toremifene is a chlorinated derivative of tamoxifen, developed to improve its risk-benefit profile. The International Breast Cancer Study Group (IBCSG) conducted two complementary randomized trials for peri- and postmenopausal patients with node-positive breast cancer to compare toremifene versus tamoxifen as the endocrine agent and simultaneously investigate a chemotherapy-oriented question. This is the first report of the endocrine comparison after a median follow-up of 5.5 years. Patients and methods: 1035 patients were available for analysis: 75% had estrogen receptor (ER)-positive primary tumors, the median number of involved axillary lymph nodes was three and 81% received prior adjuvant chemotherapy. Results: Toremifene and tamoxifen yielded similar disease-free (DFS) and overall survival (OS): 5-year DFS rates of 72% and 69%, respectively [risk ratio (RR)=0.95; 95% confidence interval (CI)=0.76-1.18]; 5-year OS rates of 85% and 81%, respectively (RR = 1.03; 95% CI = 0.78-1.36). Similar outcomes were observed in the ER-positive cohort. Toxicities were similar in the two treatment groups with very few women (
KW - Adjuvant therapy
KW - Early-stage breast cancer
KW - Tamoxifen
KW - Toremifene
UR - http://www.scopus.com/inward/record.url?scp=10944221233&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=10944221233&partnerID=8YFLogxK
U2 - 10.1093/annonc/mdh463
DO - 10.1093/annonc/mdh463
M3 - Article
C2 - 15550579
AN - SCOPUS:10944221233
VL - 15
SP - 1749
EP - 1758
JO - Annals of Oncology
JF - Annals of Oncology
SN - 0923-7534
IS - 12
ER -